Royalty Pharma PLC $RPRX Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 60.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,174 shares of the biopharmaceutical company’s stock after acquiring an additional 14,774 shares during the period. Nisa Investment Advisors LLC’s holdings in Royalty Pharma were worth $2,286,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Bank of America Corp DE boosted its holdings in Royalty Pharma by 29.0% in the 1st quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock valued at $167,696,000 after purchasing an additional 786,921 shares during the period. Amundi increased its holdings in shares of Royalty Pharma by 15.3% in the first quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock worth $148,168,000 after purchasing an additional 409,394 shares during the period. Dorsey Asset Management LLC increased its holdings in shares of Royalty Pharma by 0.8% in the first quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock worth $109,207,000 after purchasing an additional 17,101 shares during the period. Hsbc Holdings PLC increased its holdings in shares of Royalty Pharma by 2,562.2% in the first quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock worth $74,000,000 after purchasing an additional 1,486,020 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in shares of Royalty Pharma by 0.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,273,705 shares of the biopharmaceutical company’s stock worth $61,100,000 after buying an additional 5,661 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on RPRX shares. Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. JPMorgan Chase & Co. upped their target price on Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. Finally, Wall Street Zen downgraded Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 26th. Eight research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $61.57.

Royalty Pharma Price Performance

RPRX stock opened at $63.86 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. Royalty Pharma PLC has a one year low of $35.92 and a one year high of $64.38. The stock has a market cap of $36.72 billion, a PE ratio of 44.04, a P/E/G ratio of 1.75 and a beta of 0.42. The firm has a 50 day simple moving average of $59.83 and a two-hundred day simple moving average of $56.22.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The firm had revenue of $674.14 million for the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. On average, analysts predict that Royalty Pharma PLC will post 5.29 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.5%. Royalty Pharma’s payout ratio is 64.83%.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the completion of the sale, the executive vice president owned 270,401 shares of the company’s stock, valued at $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of Royalty Pharma stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 208,252 shares of company stock worth $12,324,407. 18.84% of the stock is owned by insiders.

Royalty Pharma Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.